Skip to main content
Explore URMC

menu

Lung Cancer: "Lung-MAP" S1400 ~ Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer

Research Question:
Will cancer cells respond better to standard treatment or one of the investigational treatments when treatment is chosen based on genes and proteins within the cancer cells called "biomarkers'?

Basic Study Information

Purpose:
The purpose of this study screening step is to perform genetic tests on your tumor sample for certain features that investigational targeted agents used in this study are specifically designed to work against. The purpose of the treatment part of this study is to compare the effects, good and bad, of these investigational agents to the usual approach to treating your type of cancer. It may be possible that you will not be able to participate in the treatment part of this study. This could happen if it is unsafe for you to receive the investigational treatment. You may also choose to not participate in the treatment portion of the study. Before you decide to get treatment on the study, you will be given information about the study treatment and you will be asked if you wish to continue on this research study. The study has two steps: • The initial screening step where we will examine your tumor tissue, and • The sub-study treatment step which will be discussed in a separate consent form. There will be many sub-studies that are open for patients at a given time. The sub-study that you will be offered will depend on a combination of the results of the testing done on your tumor sample, and which sub-studies are available when you are ready to get treatment on this study. The testing done on you tumor sample is examining the presence or absence of certain biomarkers. These biomarkers are either changes in genes or proteins in cancer cells that may be associated with cancer growth. If your tumor has just one biomarker with a sub-study designed for that biomarker, you will be assigned to that sub-study. If your tumor has multiple biomarkers with sub-studies designed for them, you will be assigned to one of the related biomarker sub-studies randomly (by chance). Additionally, once you are assigned to a sub-study, a computer will assign you by chance to one of the treatment groups in the sub-study. This is called “randomization.” This is done by chance because no one knows if one treatment is better or worse than the other. In each of the sub-studies an investigational treatment will be compared to a standard treatment.

Location: cancer center
Study Web URL:  http://clinicaltrials.gov/ct2/show/NCT02154490?term=Phase+II%2FIII+Biomarker-Driven+Master+Protocol+for+Second+Line+Therapy+of+Squamous+Cell+Lung+Cancer&rank=1
Study Reference #: CLUN-14066

Lead Researcher (Principal Investigator)

Lead Researcher: Eric Kim

Study Contact Information

Study Coordinator: Amy Jasek
Phone: (585) 273-1912
Email: Amy_Jasek@urmc.rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Carcinoma, Squamous Cell

More information about Lung Cancer

Return to Search